IN2014MN01227A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01227A
IN2014MN01227A IN1227MUN2014A IN2014MN01227A IN 2014MN01227 A IN2014MN01227 A IN 2014MN01227A IN 1227MUN2014 A IN1227MUN2014 A IN 1227MUN2014A IN 2014MN01227 A IN2014MN01227 A IN 2014MN01227A
Authority
IN
India
Prior art keywords
patient
methods
relates
heart
heart damage
Prior art date
Application number
Inventor
Xinhua Yan
Anthony O Caggiano
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of IN2014MN01227A publication Critical patent/IN2014MN01227A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)

Abstract

The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designed to treat a damaged heart in a patient.
IN1227MUN2014 2007-05-10 2008-05-12 IN2014MN01227A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92854107P 2007-05-10 2007-05-10
PCT/US2008/006060 WO2008140814A1 (en) 2007-05-10 2008-05-12 Methods for detecting cardiac damage

Publications (1)

Publication Number Publication Date
IN2014MN01227A true IN2014MN01227A (en) 2015-07-03

Family

ID=40002559

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1227MUN2014 IN2014MN01227A (en) 2007-05-10 2008-05-12

Country Status (11)

Country Link
US (5) US8628929B2 (en)
EP (1) EP2153228A4 (en)
JP (5) JP5749490B2 (en)
CN (2) CN101743474B (en)
AU (1) AU2008251822B2 (en)
BR (1) BRPI0810631A2 (en)
CA (2) CA2965208C (en)
IN (1) IN2014MN01227A (en)
MX (2) MX2009012174A (en)
RU (1) RU2498309C2 (en)
WO (1) WO2008140814A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2498309C2 (en) 2007-05-10 2013-11-10 Акорда Терапьютикс, Инк. Methods for detecting cardiac disorders
CN102159237A (en) 2008-08-15 2011-08-17 阿索尔达治疗公司 Compositions and methods for treatment during non-acute periods following cns neurological injury
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
EP2808339B1 (en) * 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
US8652788B2 (en) * 2009-12-02 2014-02-18 Abbott Laboratories Assay for diagnosis of cardiac myocyte damage
US8835120B2 (en) * 2009-12-02 2014-09-16 Abbott Laboratories Assay for cardiac troponin-T (cTnT)
EP2555788B1 (en) 2010-03-24 2017-10-11 Massachusetts Institute of Technology NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY.
EP2796874B1 (en) * 2010-08-26 2017-03-08 Roche Diagnostics GmbH Use of biomarkers in monitoring a medication in a subject suffering from heart failure
BR112017005730B1 (en) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc METHOD FOR SCREENING AN INDIVIDUAL FOR THE RISK OF A CARDIOVASCULAR EVENT OR FOR PREDICTING THE LIKELIHOOD THAT AN INDIVIDUAL WILL HAVE SUCH AN EVENT
RU2585391C1 (en) * 2014-12-19 2016-05-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Чеченский государственный университет Method for immunological prediction of small myocardial damage
MA42936A (en) * 2015-09-25 2018-08-01 Douglas B Sawyer HEART INJURY TREATMENT PROCESS
RU2648529C1 (en) * 2016-12-27 2018-03-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Estimation method of the efficiency of medical therapy in adult patients with acute heart failure after operations in bare heart, receiving treatment with the method of extracorporal membrane oxygenation
RU2709458C2 (en) * 2017-12-22 2019-12-18 Марина Александровна Чичкова Method for optimization of early immunological diagnostics of complications of percutaneous coronary intervention in patients with ihd
RU2722111C1 (en) * 2019-12-30 2020-05-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method of managing patients with chronic lymphatic leukemia in a polychemotherapy according to a fcr scheme aimed at preventing cardiotoxicity
RU2749552C1 (en) * 2020-08-03 2021-06-15 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Method for selecting patients with long-term persistent atrial fibrillation for effective catheter treatment
RU2760242C1 (en) * 2021-03-01 2021-11-23 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени В.А. Алмазова" Министерства здравоохранения Российской Федерации Method for assessing myocardial damage and risk of complications development after cardiac surgery
CN113238060B (en) * 2021-05-08 2022-10-11 迈克生物股份有限公司 Kit for predicting or diagnosing myocarditis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5324502A (en) * 1992-04-02 1994-06-28 Purdue Research Foundation Radiopharmaceuticals for imaging the heart
US6092695A (en) 1992-05-11 2000-07-25 Cytologix Corporation Interchangeable liquid dispensing cartridge pump
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6653249B1 (en) * 2000-05-25 2003-11-25 Penn Emblem Corporation Emblem having calendered fabric layer
GB0029154D0 (en) * 2000-11-30 2001-01-17 Lee Helen Signal enhancement with multiple labelled-antibodies
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN1267590C (en) * 2004-06-11 2006-08-02 清华大学 Preparing method for growth factor slow-releasing system for tissue repair
CN1715926B (en) * 2004-07-02 2011-08-17 上海泽生科技开发有限公司 Use of neuregulin mutant
WO2007011757A1 (en) 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
US7776817B2 (en) 2005-09-02 2010-08-17 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
RU2498309C2 (en) 2007-05-10 2013-11-10 Акорда Терапьютикс, Инк. Methods for detecting cardiac disorders
DE102007061117A1 (en) 2007-12-19 2009-06-25 Robert Bosch Gmbh Electrical contact
US20130143805A1 (en) 2010-08-13 2013-06-06 Georgetown University Ggf2 and methods of use

Also Published As

Publication number Publication date
JP6636402B2 (en) 2020-01-29
JP6978553B2 (en) 2021-12-08
US8628929B2 (en) 2014-01-14
JP5749490B2 (en) 2015-07-15
CN104614510A (en) 2015-05-13
AU2008251822A1 (en) 2008-11-20
US20140378377A1 (en) 2014-12-25
CA2686959A1 (en) 2008-11-20
US20180028610A1 (en) 2018-02-01
CN104614510B (en) 2017-07-04
CN101743474B (en) 2015-06-03
JP5998171B2 (en) 2016-09-28
CA2686959C (en) 2017-06-13
AU2008251822B2 (en) 2014-02-06
US20160263192A1 (en) 2016-09-15
CN101743474A (en) 2010-06-16
WO2008140814A1 (en) 2008-11-20
US20110085976A1 (en) 2011-04-14
MX2009012174A (en) 2010-03-30
US20190269759A1 (en) 2019-09-05
US11071770B2 (en) 2021-07-27
BRPI0810631A2 (en) 2017-05-09
US9757429B2 (en) 2017-09-12
US10258667B2 (en) 2019-04-16
MX348082B (en) 2017-05-25
JP2020176138A (en) 2020-10-29
EP2153228A1 (en) 2010-02-17
JP2019010123A (en) 2019-01-24
JP2014122923A (en) 2014-07-03
EP2153228A4 (en) 2010-08-04
CA2965208A1 (en) 2008-11-20
JP2017026622A (en) 2017-02-02
US9329171B2 (en) 2016-05-03
JP2010527000A (en) 2010-08-05
RU2009145695A (en) 2011-06-20
RU2498309C2 (en) 2013-11-10
CA2965208C (en) 2022-06-14

Similar Documents

Publication Publication Date Title
IN2014MN01227A (en)
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
NZ593474A (en) Compositions and methods for treatment of celiac disease
IL209231A0 (en) Scoring catheter for treating diseased heart valves
WO2010091049A3 (en) Diagnosis and treatment of cancer
IL210724A (en) Apparatus for treating cardiac tissue
WO2011092285A3 (en) Means and methods for diagnosing heart failure in a subject
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
MX336145B (en) Method of treating chronic heart failure.
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
EA201190337A1 (en) METHOD OF TREATMENT
EP2171450A4 (en) Adamts4 as a blood biomarker and therapeutic target for chronis renal failure
PH12014500301A1 (en) Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
PH12013500559A1 (en) Combination therapy for treating hcv infection
PL2429606T3 (en) Method and apparatus for optimizing an extracorporeal blood treatment
GB202406210D0 (en) Treatment methods for als patients
MX2010000938A (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder.
EA200901062A1 (en) USING INHIBITORS OF SOLUBLE EPOXYDHYDROLASE FOR THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME AND RELEVANT DISORDERS
GB201121914D0 (en) Method for patient selection
MX2011012538A (en) Combination therapy for the treatment of multiple myeloma.
PH12014500973A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies
MX2007003790A (en) Treatment method.
WO2011133479A3 (en) Combination therapy with a proteasome inhibitor and a gallium complex
EA201491836A1 (en) METHODS OF CANCER TREATMENT USING PI3K INHIBITOR AND MEK INHIBITOR
WO2012129145A8 (en) Nsclc combination therapy